Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions
Inflammatory Arthritis
Interventions
DRUG

LY3114062 SC

LY3114062 administered SC.

DRUG

Placebo

Placebo administered SC.

DRUG

LY3114062 IV

LY3114062 administered IV.

Trial Locations (4)

1612

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sofia

50159

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest

0112

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tbilisi

MD2025

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chisinau

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02144272 - Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis | Biotech Hunter | Biotech Hunter